Pipeline

Pipeline

R&D Pipeline and
Development Status

  • Project Candidate
  • Target Disease
  • Discovery
  • Preclinical
  • IND
  • Phase 1
  • Phase 2

GIC-102
(T.O.P. NK®)

Solid / Hematologic cancers

Phase 2a
  • Description : NK cell therapy activated and amplified using ONLY the ancillary proteins. Without genetic modification or viral transduction, CD16 expression and cytotoxic granule contents are HIGHLY ELEVATED in T.O.P. NK cells.
  • Technology : NKPURE Expander® Platform
  • Partnership Proposal : T.O.P. NK® Platform (T.O.P. NK® is the cell-based platform. We can develop the platform to various cell therapies like CAR-NK, Nano NK)

GIC-101
(Nano NK®)

Solid cancers

  • Description : Allogeneic NK cell reinforced with chemo-loaded nanoparticles
  • Technology : NKPURE Expander® Platform, T.O.P. NK®

GIC-302
(Drone Treg®)

Inflammatory Bowel Disease

  • Description : Autologous regulatory T cell highly expressing organ specific homing receptors for the treatment of inflammatory disease
  • Technology : TregPure ExpanderTM Platform
  • Partnership Proposal : Drone Treg® Platform (Drone Treg® is the cell-based platform. We can develop the platform to various cell therapies like CAR-Treg)

CAR NK

Solid/ Hematologic cancer

  • Description :Allogeneic NK cell therapies with Chimeric Antigen Receptors(CAR)
  • Technology : NKPURE Expander® Platform
  • Partners : HK inno.N, Cartexell, T.O.P. NK®

T.O.P. NK® : Immunological Synapse observed by Scanning Electron Microscope